Saturday, June 3, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home CBRNE

CounterACT Grants for Chemical Countermeasures Research

by Global Biodefense Staff
October 20, 2015
NIH CounterACT Chemical Countermeasure Program

The National Institutes of Health (NIH) CounterACT program fosters and supports research and development of new and improved therapeutics for chemical threats, including traditional chemical warfare agents, toxic industrial chemicals, and pesticides.

In Fiscal Year 2015, the following awards were made in the chemical defense medical countermeasures research area:

U01 Cooperative Research Awards

Blocking Arsenicals-induced Cutaneous Injury
Mohammad Athar, Ph.D. University of Alabama at Birmingham

Development of the Vitamin B12 Analog Cobinamide as a Hydrogen Sulfide Antidote
Gerry R. Boss, M.D. University of California San Diego

Bromine Inhalation Induced Lung Injury: Novel Mechanisms and Treatment Strategies
Sadis Matalon, Ph.D. University of Alabama at Birmingham

Molecular Imaging of Chemical Threats and Countermeasures
Charles M. Thompson, Ph.D. University of Montana Missoula

R21 Exploratory/Developmental Grants

Targeting the Glutamatergic System to Counteract Soman Toxicity in Immature Rats
Maria F.M. Braga, D.D.S., Ph.D. Uniformed Services University of the Health Sciences

Therapy for Ocular Mustard Gas Exposure Using Engineered FGF Derivatives
David D. Eveleth, Ph.D. E&B Technologies, LLC

Mechanisms and Countermeasures of Halogen-Induced Injury to Pregnant Mice
Sadis Matalon, Ph.D. University of Alabama at Birmingham

Amelioration of Soman-Induced Neuropathology with NAAG-related Compounds
Joseph T. McCabe, Ph.D. Uniformed Services University of the Health Sciences

Glutathione Monoesters to Counteract Ocular Chemical Injury
Vasilis Vasiliou, Ph.D. Yale University

Atropine for Chlorine Inhalation Toxicity
Livia A. Veress, M.D.
University of Colorado, Denver

CounterACT is part of the U.S. Health and Human (HHS) Services Public Health Emergency Medical Countermeasures Enterprise (PHEMCE), which coordinates medical countermeasure efforts across HHS and federal interagency partners. This NIH-led program includes a comprehensive network of Research Centers of Excellence, individual co-operative research projects, small business innovation research grants, contracts, and interagency agreements with the Department of Defense.

Tags: AntitoxinsAwards

Related Posts

Vials of finished vaccines
Funding News

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics
Industry News

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023
Medical Countermeasures

Scientists Design Molecule to Slow SARS-Cov-2 Infection

March 29, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Load More

Latest News

Vials of finished vaccines

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

April 26, 2023
Biodefense Headlines – 25 April 2023

Biodefense Headlines – 25 April 2023

April 25, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2023 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2023 Stemar Media Group LLC